Montanide
PreclinicalSmall molecule
Montanide is one of 13 small molecule programs targeting Myeloid Neoplasm. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Myeloid Neoplasm
#DrugCompanyPhaseTrials
1Venclexta
AbbViePhase 3
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 2
CPX-351
Jazz PharmaceuticalsPhase 2
Dacogen
Sun Pharmaceutical Industries, Inc.Phase 1
Jakafi
IncytePhase 1
Cedazuridine
TakedaPhase 3
ASTX030
Taiho Oncology, Inc.Phase 3
Navitoclax
AbbViePhase 1
Leukine
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Myeloid Neoplasm1 trial
Vaccination1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Montanide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- NNYU Langone Health